Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: Female

Summary

Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer. Patients will be randomized to letrozole (2.5 mg per day for 5 years) vs anastrozole (1 mg per day for 5 years). Follow up will occur for 5 years after the completion of enrollment for survival and disease status updates.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Anastrozole; Hormones; Letrozole

Criteria

Inclusion Criteria:

• Recent primary surgery for breast cancer

• Early stage breast cancer

• Postmenopausal

• Hormone receptor positive

• Positive lymph node involvement

Exclusion Criteria:

• Metastatic disease

• Presence of contralateral breast cancer including DCIS

• Progression

Other protocol-defined inclusion/exclusion criteria may apply.